外科理论与实践2024，Vol.29Issue(1)：10-13,4.DOI:10.16139/j.1007-9610.2024.01.03
2023年第2版《NCCN胰腺癌临床实践指南》更新解读
Interpretation of 2023 2nd NCCN clinical practice guidelines in oncology-pancreatic adenocarcinoma
摘要
Abstract
Pancreatic adenocarcinoma,a severe digestive malignancy,is characterized by its poor prognosis.The National Comprehensive Cancer Network(NCCN)persistently refines its guidelines,integrating cutting-edge evidence-based medical insights to standardize the diagnostic and therapeutic strategies of pancreatic adenocarcinoma.The NCCN clinical practice guidelines in oncology-pancreatic adenocarcinoma were updated twice on May 4 and June 19,2023,respectively.Compared to the 2022 predecessor,these two updates placed a particular emphasis on immunotherapy/targeted therapy,the introduction of NALIRIFOX regimen,and supplementary treatment protocols for patients with intermediate performance status.This article provided an interpretation of the latest updates to the NCCN clinical practice guidelines in oncology-pancreatic adenocarcinoma,integrating relevant evidence-based medical findings.关键词
胰腺癌/美国国立癌症综合网络(NCCN)/指南/解读Key words
Pancreatic adenocarcinoma/National Comprehensive Cancer Network(NCCN)/Guideline/Interpretation分类
临床医学引用本文复制引用
陈佳浩,姜翀弋..2023年第2版《NCCN胰腺癌临床实践指南》更新解读[J].外科理论与实践,2024,29(1):10-13,4.基金项目
国家自然科学基金(82372968) （82372968）
上海市申康医院发展中心项目(SHDC2024CRI080) （SHDC2024CRI080）
复旦大学医学工程联合基金(XM03231533) （XM03231533）
